---
title: Incidence and Predictors of Post-TIPS Heart Failure in Patients With Cirrhosis
nct_id: NCT05596253
overall_status: UNKNOWN
sponsor: West China Hospital
study_type: OBSERVATIONAL
primary_condition: Liver Cirrhosis
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05596253.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05596253"
ct_last_update_post_date: 2024-04-12
last_seen_at: "2026-05-12T06:25:44.513Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Incidence and Predictors of Post-TIPS Heart Failure in Patients With Cirrhosis

**Official Title:** Incidence and Predictors of Post-TIPS (Transjugular Intrahepatic Portosystemic Shunt (TIPS) Heart Failure in Patients With Cirrhosis

**NCT ID:** [NCT05596253](https://clinicaltrials.gov/study/NCT05596253)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** West China Hospital
- **Conditions:** Liver Cirrhosis, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Heart Failure
- **Start Date:** 2022-10-11
- **Completion Date:** 2025-07
- **CT.gov Last Update:** 2024-04-12

## Brief Summary

The purpose of this study is to conduct a prospective trial to investigate the incidence of heart failure in cirrhosis patients undergoing transjugular intrahepatic portosystemic shunt ,and to analyze the the predictors and modififications of cardiac function.

## Detailed Description

Hyperdynamic circulation is a common Phenomenon in cirrhosis due to systemic and splanchnic vasodilatation, which may result cardic dysfunction and abnormal structure ,called cirrhotic cardiomyopathy(CCM). Transjugular intrahepatic portosystemic shunt (TIPS), as a effective technique to alleviates portal hypertension in cirrhotic patients, often be used to treat with refractory ascites and variceal bleeding which endoscopy and drug therapy are ineffective. However, owing to the increased shunting of blood from the splanchnic vascular bed into the central vascular bed, TIPS further exacerbates the hyperdynamic circulatory state, which may lead to heart failure.yet there are no convincing research to study the incidence of heart failure in cirrhosis after transjugular intrahepatic portosystemic shunt. The purpose of this study is to conduct a prospective trial to investigate the incidence of heart failure in cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt ,and to analyze the the predictors and modififications of cardiac function.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Cirrhosis
2. TIPS is placed successfully
3. Agree to participate in the trial

Exclusion Criteria:

1. Non-cirrhotic portal hypertension
2. Previous TIPS or surgical shunt
3. Medium to severe pulmonary hypertension
4. Heart failure
5. End-stage renal disease requiring hemodialysis
6. Respiratory failure
7. Malignancies with a life expectancy of less than 6 months
```

## Arms

- **Patients with cirrhosis who underwent TIPS** — Patients with cirrhosis who underwent TIPS due to complications of portal hypertension were inclueded for observation.

## Interventions

- **TIPS** (PROCEDURE) — TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.

## Primary Outcomes

- **Incidence of heart failue** _(time frame: up to 36 months)_ — Heart failue assessed by2021 ESC Guidelines

## Secondary Outcomes

- **Predictors of heart Failure** _(time frame: up to 36 months)_
- **mortality** _(time frame: up to 36 months)_
- **Modififications of cardiac function** _(time frame: up to 36 months)_

## Locations (1)

- West China Hospital of Sichuan University, Chengdu, Sichuan, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.west china hospital of sichuan university|chengdu|sichuan|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05596253.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05596253*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*